HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx June 1, 2023 0 Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS May 30, 2023 0 Bio-Techne ExoDx Prostate Test is More Accurate in High- and Low-Risk Patients Compared to Standard of Care May 18, 2023 0 Celldex Therapeutics Presented Positive Preclinical Data from its TSLP/SCF Bispecific Antibody Program CDX-622 at AAI May 15, 2023 0